Gilead Sciences, Inc. $GILD Shares Bought by Waverly Advisors LLC

Waverly Advisors LLC lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 27.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 33,822 shares of the biopharmaceutical company’s stock after purchasing an additional 7,354 shares during the quarter. Waverly Advisors LLC’s holdings in Gilead Sciences were worth $4,714,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in GILD. Brighton Jones LLC boosted its stake in shares of Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after acquiring an additional 2,450 shares in the last quarter. Bison Wealth LLC purchased a new position in shares of Gilead Sciences in the 4th quarter valued at about $215,000. Sivia Capital Partners LLC raised its holdings in Gilead Sciences by 16.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock worth $464,000 after purchasing an additional 602 shares during the period. Ieq Capital LLC boosted its position in Gilead Sciences by 12.0% during the second quarter. Ieq Capital LLC now owns 118,695 shares of the biopharmaceutical company’s stock worth $13,160,000 after purchasing an additional 12,705 shares in the last quarter. Finally, Diversify Advisory Services LLC grew its holdings in Gilead Sciences by 18.6% in the second quarter. Diversify Advisory Services LLC now owns 4,296 shares of the biopharmaceutical company’s stock valued at $516,000 after purchasing an additional 674 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Gilead Sciences

In related news, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $123.92, for a total transaction of $371,760.00. Following the completion of the sale, the insider owned 124,234 shares of the company’s stock, valued at approximately $15,395,077.28. This represents a 2.36% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $126.29, for a total transaction of $1,894,350.00. Following the completion of the sale, the chief executive officer owned 607,133 shares of the company’s stock, valued at approximately $76,674,826.57. The trade was a 2.41% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 67,000 shares of company stock valued at $8,687,140 over the last 90 days. 0.30% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Rothschild & Co Redburn reduced their target price on Gilead Sciences from $170.00 to $167.00 in a research note on Monday, May 11th. Weiss Ratings lowered shares of Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, May 28th. Leerink Partners cut shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $146.00 to $127.00 in a research report on Tuesday, July 21st. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $155.00 price objective on shares of Gilead Sciences in a report on Monday, July 6th. Finally, Maxim Group upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 target price on the stock in a research report on Wednesday, May 20th. Twenty-five analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $158.30.

Gilead Sciences Stock Performance

Shares of NASDAQ:GILD opened at $134.32 on Wednesday. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77. Gilead Sciences, Inc. has a 1 year low of $108.46 and a 1 year high of $157.29. The firm has a market capitalization of $166.77 billion, a PE ratio of 18.30 and a beta of 0.32. The business’s 50 day moving average price is $129.64 and its 200-day moving average price is $135.75.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating the consensus estimate of $1.91 by $0.12. The firm had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The firm’s revenue was up 4.4% compared to the same quarter last year. During the same period in the prior year, the company earned $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, equities research analysts expect that Gilead Sciences, Inc. will post -0.77 earnings per share for the current fiscal year.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Morgan Stanley maintained an Overweight rating on Gilead and only modestly reduced its price target to $165 from $166, implying substantial potential upside based on the recent trading level. The endorsement supports sentiment toward Gilead’s valuation and outlook. Benzinga analyst update
• Positive Sentiment: Gilead’s shares outperformed the market during the latest session, suggesting investors may be responding to the company’s defensive profile, strong profitability and established product portfolio. Its most recent reported quarter exceeded consensus estimates for both earnings and revenue, providing a supportive backdrop. Gilead Sciences outperforms the market
• Neutral Sentiment: Broader biopharmaceutical industry developments, including digital bioprocessing and prediction-market discussions related to drug research, do not appear to create a direct near-term catalyst for Gilead. Bioprocessing Summit 2026
• Negative Sentiment: Zacks expects Gilead to report a decline in upcoming earnings and says the company lacks the combination of positive earnings revisions and estimates typically associated with a likely earnings beat. This could limit upside or increase volatility ahead of the results. Gilead earnings expectations

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.